Literature DB >> 2810438

Observation of activity of IL-2 produced by mononuclear cells in tumor draining lymph-node.

J M Fang, A H Bi.   

Abstract

The activity of IL-2 produced by mononuclear cells in draining lymph-onde and peripheral blood from patients with cancer was investigated. It was found that, though the activity of IL-2 produced by peripheral blood mononuclear cells from these patients became much lower, the activity of IL-2 produced by draining lymph node mononuclear cells from the same donors showed no decline, in contrast to non-malignant patients and healthy controls. What is more, the NK cells of tumor draining lymph-nodes responded as strong to xenogenous IL-2 as those of draining lymphnodes from patients with non-malignant disease. The results suggested that some of the immune functions of tumor draining lymph-node mononuclear cells might be more stable than those of peripheral blood mononuclear cells in patients suffering from cancer, and that local injection of xenogenous IL-2 might enhance the anti-cancer activity of tumor draining lymph-node.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2810438     DOI: 10.1007/bf02908933

Source DB:  PubMed          Journal:  J Tongji Med Univ        ISSN: 0257-716X


  4 in total

1.  Separation of leukocytes from blood and bone marrow. Introduction.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

2.  A comparison of PGE2 effects on human suppressor cell function and on interleukin 2 function.

Authors:  A B Tilden; C M Balch
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

3.  The purification and properties of human T cell growth factor.

Authors:  J W Mier; R C Gallo
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

4.  Diminished interleukin-2 activity production in cancer patients bearing solid tumors and its relationship with natural killer cells.

Authors:  A Rey; B Klein; D Zagury; C Thierry; B Serrou
Journal:  Immunol Lett       Date:  1983-03       Impact factor: 3.685

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.